N. Chieffo

Abiraterone and increased survival in metastatic prostate cancer.

Arturo Molina, Tina Cheng, Fred Saad, 2011, The New England journal of medicine.

Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.

A. Gottlieb, M. Lebwohl, Sewon Kang, 2004, Clinical immunology.

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.

D. Tsavachidou, P. Troncoso, C. Logothetis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.

L. Gordon, M. Czuczman, J. Friedberg, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of "intracrine androgen signaling signature'' to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC).

P. Troncoso, C. Logothetis, S. Tu, 2010 .